ERYTECH Pharma to partner with Teva for long term distribution agreement in Israel Post author:admERY Post published:May 17, 2011 Post category:Newsroom ERYTECH Pharma is pleased to announce it has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of Graspa®, the company‟s lead product, in Israel. You Might Also Like ERYTECH collaborates with Fox Chase Cancer Center to advance its platform in the field of rare metabolic disorders March 23, 2017 ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018 April 12, 2018 ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders July 12, 2017
ERYTECH collaborates with Fox Chase Cancer Center to advance its platform in the field of rare metabolic disorders March 23, 2017
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018 April 12, 2018
ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders July 12, 2017